Why partners choose our network
The drug development and manufacturing challenges biotech and pharmaceutical companies most commonly bring to us:
Challenge
|
How we solve it
|
Need
to get to clinic fast
|
First-in-human quick-to-clinic option: cGMP drug product from drug substance with minimal formulation development. |
| Too many vendors across the lifecycle |
One
network: formulation development through cGMP manufacturing, QC, packaging and
regulatory. |
| Regulatory compliance across markets
|
FDA, MHRA, ANVISA and beyond. 5 FDA inspections. 12 non-US market audits. |
| Current CDMO has no proven path from concept to commercial |
9
products approved. 6 currently being produced for the
US and international markets. |
Our approach
Bringing a drug product to market shouldn't mean navigating unnecessary complexity. Fragmented outsourcing can slow progress, introduce risk, and dilute critical know how. Our model is designed differently. A single pharmaceutical development partner supports your drug product from early formulation through commercial readiness, bringing scientific, operational, and regulatory expertise together within one connected ecosystem.
Our integrated network is supported by experienced teams with deep capabilities spanning pre‑clinical development through commercialization, across both oral solid dosage and inhaled drug products. The same formulation, analytical, and regulatory insight that shapes your product early on remains with it as you scale enabling efficient technology transfer, consistent project execution, and a smoother path to market access.
Therapeutic areas
Our drug development and manufacturing services support biotech and pharma programs across:
Oncology and HPAPIs
Respiratory and inhalation
CNS
Metabolic and chronic diseases
Oral peptides
Rare diseases
